News
-
1 min
iQure Pharma’s Lead Therapeutic Advances in the NIH Preclinical Screening Platform for Pain (PSPP)
-
2 min
iQure Pharma Targets Future with New Board Appointments
-
1 min
iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Pain
-
1 min
iQure Pharma Will Present at Mid-Atlantic Diamond Venture 2022 Spring Forum
-
1 min
iQure Pharma is Investment-Ready — Will Present at Keiretsu Forum Mid-Atlantic
-
1 min
iQure Pharma Awarded Patent for Therapy to Treat Pain and Epilepsy
-
1 min
iQ-008 Accepted into NIH Preclinical Screening Platform for Pain (PSPP)
-
1 min
Novel and promising mechanism of action for new pain candidate iQ-007 confirmed
-
2 min
Company signed Agreement with University of Arizona for non-opioid treatment of post-operative pain
-
1 min
Preliminary Subchronic Toxicology Study Results Indicate iQ-007 Has Favorable Safety Profile
-
1 min
iQure Pharma Inc. Secures Private Investment of $100,000
